Core Viewpoint - Silicon Treasure Technology (300019.SZ) has stated that the company currently does not have any products applied in the brain-computer interface sector [1] Company Summary - Silicon Treasure Technology has clarified its position regarding the development of products for brain-computer interfaces, indicating no current involvement in this area [1]

证券日报网讯博济医药8月13日在互动平台回答投资者提问时表示，公司控股子公司九泰药械是一家专 注于医疗器械第三方外包服务的CRO公司，主要为客户提供医疗器械相关的临床试验以及注册申报服 务，目前暂无脑机接口领域相关的项目。九泰药械积极关注脑机接口相关领域，也有能力为脑机接口医 疗器械的注册及临床试验提供全流程服务。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that Innovation Medical's stock experienced a significant price fluctuation, with a cumulative increase of over 20% in three consecutive trading days [1] - Innovation Medical announced its investment in Bole Brain Machine (Hangzhou) Technology Co., Ltd., holding a 40% stake in the company [1] - Bole Brain Machine focuses on the research and development of core brain-machine interface technologies and related product design and production, primarily targeting the medical rehabilitation sector [1] Group 2 - As of the announcement date, Bole Brain Machine's products have not been officially launched, and only a small number of products have been sold through collaborations with research institutions [1] - The operating losses for Bole Brain Machine are projected to be 6.6017 million yuan in 2023 and 8.6641 million yuan in 2024 [1]

36氪获悉，小鹏汽车在微博发文宣布，小鹏G7交付量正式突破10000台，小鹏G7 Ultra版本订单占比超 过50%。 腾讯控股：上半年耗资365亿港元购回合共8186.7万股 36氪获悉，腾讯发布2025年二季度财报，财报显示，截至二零二五年六月三十日止六个月内，腾讯于联 交所以总代价约365亿港元（未计开支）购回合共81867000股股份。购回的股份其后已被注销。进行回 购旨在长远提高股东价值。 大公司： 胖东来已为珠宝产品申请多项知识产权 小鹏汽车：小鹏G7交付量正式突破10000台 36氪获悉，爱企查App显示，许昌市胖东来商贸集团有限公司已注册"东来赤金""东来璞石""东来尚 银"等国际分类为珠宝钟表的商标；已公布"项链（羽毛）""项链（自由爱）""项链（鎏）"等项链产品 外观设计专利。除此之外，许昌市胖东来商贸集团有限公旗下许昌市胖东来唯初珠宝有限公司已公 布"手镯（龙翔嘉瑞）""吊坠（陪伴）""戒指（兰芝常生）"等多项珠宝产品外观设计专利。 广汽集团：广汽埃安拟6亿元增资华望汽车 36氪获悉，广汽集团发布公告，公司控股子公司广汽埃安拟向华望汽车技术（广州）有限公司（简 称"华望汽车"）增资6亿元 ...

冲高回落后再度拉升，截止午盘沪指上涨0.51%，深成指上涨0.34%，创业板指上涨0.91%。两市合计超 3300只个股下跌，合计成交额1.19万亿。 消息面：市场监管总局：今年上半年全国新设经营主体1327.8万户。特朗普将在未来几周内做出大麻相 关决定，考虑重新划分大麻分类。马斯克表示，XAI将就应用商店问题对苹果公司采取法律行动。 欢迎您在评论中分享自己的看法，大家一起学习和讨论。 航天航空低开低走陷入调整，截止午盘下跌2.21%。其中航亚科技大跌5.16%，爱乐达、航天宏图、航 天环宇等多股跌幅均在4%上方。军工股展开调整，其中捷强装备等跌超5%。锂矿、稀土永磁、光伏等 板块跌幅居前。 脑机接口概念股表现活跃，麦澜德、翔宇医疗等股涨幅均在10%上方。新疆本地股维持强势，包括新疆 交建等在内的多股3连板。AI硬件股再度大涨，其中胜宏科技等多股再创历史新高，寒武纪涨超15%。 ...

智通财经APP讯，创新医疗(002173.SZ)发布股价异动公告称，公司2021年初参与投资设立了博灵脑机 (杭州)科技有限公司(简称"博灵脑机")，公司持有博灵脑机40%的股权。博灵脑机主要从事脑机接口核 心技术研发和相关产品的设计生产，现阶段的技术产品主要应用于医疗康复领域。截止公告日，博灵脑 机产品尚未正式上市，仅因与科研机构合作而销售少量产品。2023年、2024年，博灵脑机的经营亏损分 别为660.17万元、866.41万元。 ...

Core Viewpoint - The stock of Innovation Medical experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days from August 11 to August 13, 2025, but no undisclosed significant information affecting the stock price was found [1] Group 1 - The company confirmed that there were no significant changes in its production operations or external environment, and the controlling shareholder and actual controller did not plan any undisclosed major matters during the abnormal fluctuation period [1] - Innovation Medical holds a 40% stake in Bole Brain Machine (Hangzhou) Technology Co., Ltd., which focuses on the research and development of core brain-machine interface technologies and related product design and production [1] - Bole Brain Machine's products are primarily applied in the medical rehabilitation field, but as of the announcement date, the products have not been officially launched, with only a small number of products sold through collaboration with research institutions [1] Group 2 - The operating losses for Bole Brain Machine were reported at 6.6017 million yuan in 2023 and 8.6641 million yuan in 2024 [1]

格隆汇8月13日丨博拓生物(688767.SH)在互动平台表示，公司通过子公司杭州博肽智投企业管理有限公 司投资了杭州青石永隽医疗设备有限公司（以下简称"青石永隽"），投后占比5%。青石永隽是由浙江 大学侵入式脑机接口团队创办成立，是南湖脑机交叉研究院首个科技成果转化企业，该公司的首款产品 面向全球3亿抑郁症患者中近30%的难治性重症抑郁患者，通过装备AI算法的三类有源植入医疗器械， 为患者提供因人、因病、因时的个性化治疗方案。通过手术方式将电极植入患者大脑皮层，接触脑组织 传递神经信号，通过植入式脑深部神经刺激（DBS）精准刺激靶点进而达到重大疾病的治疗目的。目前 已进入科研性临床试验阶段，尚未取得医疗器械注册证书。 ...

Group 1 - The stock price of Aipeng Medical reached 35.74 yuan as of August 13, 2025, with an increase of 0.65 yuan, representing a rise of 1.85% from the previous trading day [1] - The opening price was 34.40 yuan, with a highest point of 35.80 yuan and a lowest point of 33.80 yuan, while the trading volume was 226,600 hands and the total transaction amount reached 795 million yuan [1] - Aipeng Medical operates in the medical device sector, focusing on pain management and nasal care, with products including microcomputer injection pumps and nasal care spray [1] Group 2 - The brain-computer interface concept became active in the afternoon, leading to significant movements in related stocks, including a rapid rebound in Aipeng Medical's stock, which saw an increase of over 2% within five minutes [1] - On August 13, the net outflow of main funds was 2.0586 million yuan, with a cumulative net outflow of 130 million yuan over the past five days [1]

Core Viewpoint - Chengyitong's stock price increased by 7.83% to 24.65 yuan, indicating strong market interest and positive investor sentiment towards the company's strategic initiatives in brain-computer interface technology [1]. Group 1: Company Performance - As of August 13, 2025, Chengyitong's stock closed at 24.65 yuan, up by 1.79 yuan from the previous trading day, with a trading volume of 542,300 shares and a total transaction value of 1.291 billion yuan [1]. - The stock opened at 22.69 yuan, reached a high of 24.87 yuan, and a low of 22.50 yuan during the trading session [1]. Group 2: Business Strategy - Chengyitong operates in the general equipment sector, focusing on smart manufacturing and rehabilitation medical devices [1]. - The company has established a dual-track strategy for brain-computer interface technology, encompassing both invasive and non-invasive approaches [1]. - In the non-invasive sector, Chengyitong is integrating existing rehabilitation devices with brain-computer interface technology to enhance product functionality and promote commercialization [1]. - The company has launched a brain-computer interface biofeedback system aimed at attention detection and training in the education sector [1]. - In the invasive sector, Chengyitong is developing a research verification center and an animal testing center for brain-computer interface technology to strengthen its R&D capabilities [1]. Group 3: Financial Flow - On August 13, 2025, the net inflow of main funds into Chengyitong was 41.04 million yuan, with a cumulative net inflow of 28.52 million yuan over the past five days [2].